吲哚布芬應用于PCI术后预防冠状动脉再狭窄的研究.docVIP

吲哚布芬应用于PCI术后预防冠状动脉再狭窄的研究 温继梨 崔晓迎 内蒙古医学院附属医院急救中心 摘要：目的：探讨吲哚布芬对PCI术后患者的冠状动脉再狭窄的预防疗效。方法：对入选的64例PCI术后患者随机分为观察组（n=32）和对照组（n=32），观察组给予吲哚布芬和氯吡格雷，对照组给予阿司匹林和氯吡格雷,进行为期6个月的观察。6个月后行冠脉造影，对两组患者的再狭窄率进行比较，对两组间的临床安全性进行比较。结果：观察组和对照组PCI术后6个月的冠脉再狭窄率相当（P0.05），两组间比较临床安全性，观察组的安全性优于对照组。结论：吲哚布芬与氯吡格雷联合使用预防冠状动脉再狭窄与阿司匹林联用氯吡格雷疗效相当，具有更好的临床应用安全性。 关键词：吲哚布芬 氯吡格雷 冠状动脉再狭窄 中图分类号：R543．3 文献标识码：B To explore the prevention effect of indobufen on PCI patients with coronary artery restenosis. Wen jili Cui xiaoying Emergency Center of the Affiliated Hospital of Inner Mongolia Abstract: Objective: To explore the prevention effect of indobufen on PCI patients with coronary artery restenosis. Methods: 64 patients with PCI were selected and randomly divided into the experiment group ( n = 32) and control group ( n = 32). The patients in experiment group were given anti-platelet indobufen and clopidogrel , in control group were given aspirin and clopidogrel for 6 months. After 6 months ,coronary angiography were done, two groups of patients with restenosis rates were compared between the two groups, to compare the clinical safety. Results: After 6 months, coronary restenosis rate ( P 0.05) were similar in the experiment group and the control group , between the two groups clinical safety, the safety of experiment group was better than the control group. Conclusion: The prevention effect of coronary artery restenosis were similar in patients between Indobufen、Clopidogrel and Aspirin、Clopidogrel, but the Indobufen and Clopidogrel was more safe. Key words: Indobufen Clopidogrel Coronary artery restenosis 近年来随着冠心病介入（Percutaneous Coronary Intervention ,PCI）技术的逐渐成熟和广泛应用，冠心病患者闭塞的血管得到及时开通，既减少了心肌梗死的面积改善了冠心病患者的预后，又降低了冠心病的死亡率。冠脉动脉粥样硬化是缺血性心脏病的基础，即使再通的血管仍然可以在粥样硬化的基础上发生再狭窄甚至闭塞。目前研究表明血小板的粘附和聚集在这个过程中起着主要的作用，因此抗血小板活性药物成为治疗冠状动脉疾病的基石。阿司匹林是目前研究实验最多而且临床应用有效性得到验证的抗血小板药物。但是由于长期应用后引起的“阿司匹林抵抗”和胃肠道的严重不良反应越来越受到重视，人们开始开发更安全有效地抗血小板药物。吲哚布芬（indobufen）能够可逆性抑制血小板环化酶，使血栓素A2(TXA2)生成减少，抑制血小板聚集，作为抗血小板药物开始应用于临床中[1,2,3]。但是关于吲哚布芬在P